Egetis Therapeutics AB (publ) (STO:EGTX)
Sweden · Delayed Price · Currency is SEK 7.24
+0.01 (0.14%)
Aug 13, 2026, 5:29 PM CET
Egetis Therapeutics AB Balance Sheet
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 142.5 | 215.8 | 351 | 303.3 | 127.7 | 144 |
Cash & Short-Term Investments | 142.5 | 215.8 | 351 | 303.3 | 127.7 | 144 |
Cash Growth | -47.76% | -38.52% | 15.73% | 137.51% | -11.32% | -49.97% |
Accounts Receivable | 5.2 | 19.2 | 15.5 | 28.2 | 3.8 | 3.5 |
Other Receivables | 7.1 | 8.7 | 8.1 | 8.2 | 6.4 | 3.3 |
Total Trade Receivables | 12.3 | 27.9 | 23.6 | 36.4 | 10.2 | 6.8 |
Inventory | 1.8 | 2.3 | 1 | 0.7 | 0.6 | 0.7 |
Other Current Assets | 6.6 | 7.5 | 4.5 | 5.5 | 8.9 | 1.4 |
Total Current Assets | 163.2 | 253.6 | 380.1 | 345.9 | 147.4 | 152.9 |
Net Property, Plant & Equipment | 9 | 9.7 | 2.6 | 4.4 | 2.7 | 4.3 |
Other Intangible Assets | 362.9 | 373.3 | 408 | 409.1 | 410.2 | 411.3 |
Long-Term Investments | 0.8 | 0.8 | 0.8 | 0.8 | 0.8 | 0.8 |
Other Long-Term Assets | 1.6 | 1.7 | 0.6 | - | - | - |
Total Assets | 537.4 | 639.1 | 792.3 | 760.2 | 561.1 | 569.3 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 23.1 | 21.8 | 25.7 | 28.7 | 20 | 4.6 |
Accrued Expenses | 170.3 | 176.7 | 137.2 | 63 | 23.7 | 17.4 |
Current Portion of Long-Term Debt | 32.4 | 31.5 | 30.1 | 5.2 | - | - |
Other Current Liabilities | 10.9 | 10.9 | 11.2 | 6.9 | 5.7 | 17.2 |
Total Current Liabilities | 236.8 | 240.9 | 204.2 | 103.9 | 49.4 | 39.2 |
Long-Term Debt | 37.9 | 45 | 84.1 | 103.4 | - | - |
Other Long-Term Liabilities | 14 | 14.5 | 11.1 | 7.3 | 5.5 | 3.1 |
Total Long-Term Liabilities | 51.9 | 59.5 | 95.2 | 110.8 | 5.5 | 3.1 |
Total Liabilities | 288.7 | 300.4 | 299.4 | 214.7 | 54.9 | 42.3 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 22.3 | 22.3 | 20.4 | 15.4 | 11.3 | 8.7 |
Additional Paid-in Capital | 2,228 | 2,228 | 2,058 | 1,780 | 1,428 | 1,263 |
Accumulated Other Comprehensive Income | 41.4 | 36.8 | 24.8 | 16.7 | 6.1 | 1.3 |
Retained Earnings | -2,043 | -1,948 | -1,610 | -1,267 | -939.6 | -745.8 |
Shareholders' Equity | 248.6 | 338.7 | 492.9 | 545.6 | 506.2 | 527 |
Total Liabilities & Equity | 537.4 | 639.1 | 792.3 | 760.2 | 561.1 | 569.3 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 70.3 | 76.5 | 114.2 | 108.6 | 0 | 0 |
Net Cash (Debt) | 72.2 | 139.3 | 236.8 | 194.7 | 127.7 | 144 |
Net Cash Growth | -58.53% | -41.17% | 21.62% | 52.47% | -11.32% | -49.97% |
Net Cash Per Share | 0.19 | 0.37 | 0.76 | 0.75 | 0.66 | 0.80 |
Book Value | 248.6 | 338.7 | 492.9 | 545.6 | 506.2 | 527 |
Book Value Per Share | 0.65 | 0.91 | 1.59 | 2.10 | 2.61 | 2.93 |
Tangible Book Value | -114.3 | -34.6 | 84.9 | 136.5 | 96 | 115.7 |
Tangible Book Value Per Share | -0.30 | -0.09 | 0.27 | 0.52 | 0.49 | 0.64 |